Ho-Young Lee Selected Research

Insulin-Like Peptides

3/2021	Insulin-Like Growth Factor Binding Protein-3 Exerts Its Anti-Metastatic Effect in Aerodigestive Tract Cancers by Disrupting the Protein Stability of Vimentin.
1/2019	Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma.
10/2016	Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation.
12/2015	Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
8/2015	Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
6/2015	Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer.
10/2014	Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
5/2014	Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer.
5/2013	A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.
8/2012	Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ho-Young Lee Research Topics

Disease

91	Neoplasms (Cancer) 05/2024 - 05/2002
49	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 05/2002
37	Lung Neoplasms (Lung Cancer) 08/2023 - 06/2002
26	Carcinogenesis 05/2024 - 02/2003
15	Squamous Cell Carcinoma of Head and Neck 03/2021 - 08/2003
13	Neoplasm Metastasis (Metastasis) 02/2023 - 09/2004
11	COVID-19 03/2024 - 01/2021
9	Hypoxia (Hypoxemia) 11/2016 - 09/2005
7	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2007
6	Body Weight (Weight, Body) 09/2023 - 04/2020
5	Colonic Neoplasms (Colon Cancer) 01/2023 - 09/2008
5	Thyroid Neoplasms (Thyroid Cancer) 01/2022 - 07/2014
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2021 - 12/2002
4	Inflammation (Inflammations) 01/2024 - 08/2002
4	Infections 12/2022 - 06/2002
4	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2019
4	Prostatic Neoplasms (Prostate Cancer) 12/2021 - 03/2021
3	Chronic Obstructive Pulmonary Disease (COPD) 01/2024 - 05/2020
3	Parkinson Disease (Parkinson's Disease) 12/2023 - 12/2008
3	Emphysema 04/2023 - 05/2020
3	Wounds and Injuries (Trauma) 07/2020 - 01/2012
3	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 01/2016
3	Adenocarcinoma 06/2015 - 12/2002
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2023 - 01/2018
2	Hypothyroidism 10/2021 - 06/2015
2	Residual Neoplasm 07/2020 - 01/2017
2	Pulmonary Emphysema 05/2020 - 05/2020

Drug/Important Bio-Agent (IBA)

26	Insulin-Like PeptidesIBA 03/2021 - 06/2002
20	Proteins (Proteins, Gene)FDA Link 04/2022 - 09/2005
19	deguelinIBA 01/2022 - 02/2003
15	Insulin-Like Growth Factor Binding Protein 3IBA 03/2021 - 06/2002
8	CarcinogensIBA 09/2023 - 11/2005
8	ErbB Receptors (EGF Receptor)IBA 01/2022 - 10/2006
7	Biomarkers (Surrogate Marker)IBA 04/2022 - 03/2008
7	Phosphotransferases (Kinase)IBA 01/2021 - 06/2003
7	IntegrinsIBA 01/2020 - 10/2013
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2015 - 01/2003
7	lonafarnib (SCH 66336)IBA 08/2012 - 08/2003
6	IodineIBA 02/2023 - 07/2014
6	Therapeutic UsesIBA 01/2023 - 01/2003
6	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2022 - 07/2009
6	Somatomedin Receptors (Somatomedin Receptor)IBA 01/2021 - 07/2011
6	Tyrosine Kinase InhibitorsIBA 01/2019 - 10/2006
6	Heat-Shock Proteins (Heat-Shock Protein)IBA 11/2016 - 09/2005
6	Insulin-Like Growth Factor I (IGF-1)IBA 05/2014 - 09/2005
6	SurvivinIBA 12/2011 - 10/2006
5	Peptides (Polypeptides)IBA 03/2024 - 08/2002
5	Glucose (Dextrose)FDA LinkGeneric 09/2023 - 01/2016
5	Insulin-Like Growth Factor Binding ProteinsIBA 06/2015 - 01/2006
4	Antineoplastic Agents (Antineoplastics)IBA 01/2023 - 07/2011
4	TransferasesIBA 01/2019 - 08/2003
4	Small Interfering RNA (siRNA)IBA 01/2018 - 11/2006
4	Insulin-Like Growth Factor II (Somatomedin A)IBA 10/2015 - 09/2009
3	LigandsIBA 12/2023 - 10/2005
3	Benzo(a)pyreneIBA 09/2023 - 11/2005
3	falcarinolIBA 08/2023 - 01/2018
3	Pancreatic Elastase (Elastase)IBA 04/2023 - 05/2020
3	VaccinesIBA 01/2023 - 01/2022
3	Neutralizing AntibodiesIBA 01/2023 - 01/2006
3	CateninsIBA 04/2022 - 01/2019
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 08/2015
3	Prostate-Specific Antigen (Semenogelase)IBA 12/2021 - 03/2021
3	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 10/2021 - 07/2014
3	Gefitinib (Iressa)FDA Link 01/2019 - 05/2007
3	LipidsIBA 01/2018 - 06/2003
3	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2017 - 09/2005
3	Proteasome InhibitorsIBA 01/2017 - 01/2008
3	4- (N- methyl- N- nitrosamino)- 1- (3- pyridyl)- 1- butanoneIBA 10/2016 - 11/2005
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2015 - 09/2005
3	cixutumumabIBA 10/2015 - 12/2011
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2011 - 09/2005
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 03/2008 - 06/2003
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 09/2005 - 06/2003
2	Bispecific AntibodiesIBA 03/2024 - 01/2023
2	Histones (Histone)IBA 01/2024 - 07/2002
2	EnzymesIBA 01/2024 - 01/2016
2	RibonucleoproteinsIBA 12/2023 - 11/2023
2	6-carboxyfluorescein (carboxyfluorescein)IBA 03/2023 - 05/2016
2	EstersIBA 03/2023 - 05/2016
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 01/2023 - 01/2021
2	evodiamineIBA 01/2023 - 01/2021
2	Monoclonal AntibodiesIBA 10/2022 - 03/2009
2	Insulin (Novolin)FDA Link 01/2022 - 05/2012
2	Thyroid HormonesIBA 10/2021 - 07/2014
2	Indicators and Reagents (Reagents)IBA 06/2021 - 11/2013
2	Coloring Agents (Dyes)IBA 01/2021 - 07/2020
2	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 07/2020 - 05/2016
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 07/2020 - 03/2009
2	Activating Transcription Factor 6IBA 07/2020 - 01/2020
2	CytokinesIBA 05/2020 - 01/2020
2	Adenosine A3 ReceptorIBA 05/2020 - 05/2020
2	gracillinIBA 04/2020 - 10/2019
2	KYA1797KIBA 01/2020 - 01/2019
2	Adenosine Triphosphate (ATP)IBA 01/2020 - 08/2015
2	Trastuzumab (Herceptin)FDA Link 11/2019 - 10/2008
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 10/2006

Therapy/Procedure

41	Therapeutics 05/2024 - 09/2004
10	Drug Therapy (Chemotherapy) 01/2022 - 01/2007
7	Chemoprevention 11/2016 - 10/2003
2	Molecular Targeted Therapy 10/2022 - 01/2018